Jigar Raythatha has spent nearly 20 years in the biotechnology industry in a variety of business functions. He rejoined Constellation in May 2017 from Jounce Therapeutics, where he held the role of chief business officer. He was the first employee at Jounce and helped build the company from its inception to a 100-person, publicly traded research and development organization. Previously, he served as head of corporate development at Constellation, where he led business development, strategy and program and alliance management functions. Prior to Constellation, Mr. Raythatha worked with Red Abbey Venture Partners, initially as a Kauffman fellow, later as a principal and finally a venture partner. Earlier in his career, Mr. Raythatha held roles of increasing responsibility at Biogen and A.T. Kearney. He earned a Master of Business Administration from Columbia University and a Bachelor of Arts in biochemistry and economics from Rutgers University.
Emma Reeve is a global finance executive who has worked in healthcare for over 20 years across pharmaceutical, medical device and bio-pharma companies. Prior to joining Constellation Pharmaceuticals, Ms. Reeve served as interim chief financial officer and corporate controller of PAREXEL International, where she was responsible for all aspects of financial reporting and accounting, investor relations, financial planning and analysis. Previously, Ms. Reeve held senior finance roles at major pharma companies including Novartis, Merck and Bristol-Myers Squibb. She was also the chief financial officer of two development-stage biotech companies, Inotek Pharmaceuticals and Aton Pharma. In addition to finance, Ms. Reeve has held senior positions in a number of countries in areas such as marketing, supply chain management and research operations. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.
Ms. Brenda Sousa joined Constellation as Vice President of Human Resources for Constellation in March 2010. Prior to joining Constellation Ms. Sousa was the Vice President of Human Resources and Operations at EPIX Pharmaceuticals, where she served as a member of the global executive management team and focused on the development and implementation of business strategy, operations, and organizational development for US companies with international offices. Before joining EPIX, she was Director of Human Resources for RKS Health Ventures and Spence Center for Women’s Health, a start-up venture that was ultimately purchased by Partners Healthcare. Prior to her human resources career, Ms. Sousa worked in the hospitality industry focusing on sales and marketing. Brenda joined the Board of Career Collaborative in 2004 where she initiated and served as Chair of the Employer Advisory Board. Brenda holds a Bachelor of Arts Degree from the University of Massachusetts.
A board-certified medical oncologist by training, Dr. Adrian Senderowicz brings to Constellation more than two decades of experience in the life sciences. As the principal investigator for a multitude of clinical trials in solid and hematological tumors, Dr. Senderowicz has significant regulatory expertise as a former clinical team leader at the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) Division of Drug Oncology Products. Prior to joining Constellation, Dr. Senderowicz served as chief medical officer at Cerulean Pharma, where he helped secure fast-track designation for the company’s lead clinical development program in two indications. Previously, Dr. Senderowicz held roles of increasing responsibility at Ignyta, Inc., Sanofi Oncology, Tokai Pharmaceuticals and AstraZeneca plc. He began his career as an investigator at the National Cancer Institute before joining the FDA’s CDER.
Brad Prosek joins Constellation Pharmaceuticals from All Terrain bioPartners LLC, where he advised and supported a global set of life sciences clients on transaction, corporate and commercial strategy as well as execution. Previously, he spent 10 years at Cubist Pharmaceuticals, where he built the company’s Market Access strategy and organization, led transaction teams responsible for deals, including the acquisition of Trius Therapeutics, supporting the company’s pipeline growth and led a new corporate venture building a complementary infection prevention business. Prior to Cubist, Mr. Prosek served in growing commercial operations and market / business development roles at Biogen, and worked as a health economics and reimbursement strategy consultant with Covance in the United States and Europe.
Dr. Sims joined Constellation Pharmaceuticals in 2008 as a founding scientist. With nearly 20 years of experience in chromatin biology and transcription, Dr. Sims helped establish Constellation’s industry-leading epigenetics platform. Dr. Sims led the discovery and translational efforts for CPI-0610, a novel BET bromodomain inhibitor currently in phase 1 clinical development for hematologic malignancies. His team’s notable work, along with others in the field, includes the discovery that BET bromodomain inhibition silences the expression of the MYC oncogene. Dr. Sims has authored more than 30 scientific publications in top-tier journals, including Science, Nature, and Cell. He received his Ph.D. in Cellular and Molecular Biology from the University of Texas at Austin and completed his postdoctoral training at UMDNJ-Robert Wood Johnson Medical School and the New York University School of Medicine.
Dr. Trojer was involved in the foundation of Constellation in early 2008 and joined the Company as a founding scientist. He has held multiple positions of increasing responsibility at Constellation. Among his many achievements, Dr. Trojer drove Constellation’s EZH2 program leading to the clinical launch of CPI-1205 currently in Ph 1 clinical trials for Lymphoma. Dr. Trojer is internationally recognized for his expertise in chromatin biology and its control of gene transcription. Dr. Trojer has authored dozens of scientific publications and is a frequent lecturer in the epigenetics space. He completed his postdoctoral studies at NYU Medical School in Dr. Danny Reinberg’s laboratory, prior to which he received both a Ph.D. in protein biochemistry and molecular biology and M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.